CONCLUSION
Discontinuation of Imatinib in FIP1L1-PDGFRA-positive HES is currently being evaluated. It is feasible, providing regular biological monitoring of CHR and CMR to detect relapse. The rapid achievement of a second remission is an additional incentive to stop the treatment.